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microRNAs (miRs) are a class of small (~22-nt) genomically encoded 
molecules that inhibit translational initiation and stimulate decay of 
mRNA targets1,2. miRs are transcribed by RNA polymerase II and proc-
essed by the RNase III enzymes—Dicer and Drosha with its binding 
partner, DGCR8—to produce short double-stranded RNAs in the 
nucleus. One strand associates with the Argonaute (Ago) protein, 
thus forming the miR-mediated silencing complex (miRISC). miRs 
guide the pairing of miRISC, with imperfect complementarity, 
to sequences in target mRNAs, thus resulting in their subsequent 
destabilization and translational repression of the target3. The ‘seed 
sequence’, at nucleotides 2–8, is a key determinant for miRISC-target 
recognition4,5. Recent data have shown that 35–40% of miR-binding 
sites are found in 3′ untranslated regions (UTRs), 40–50% in coding 
regions and <5% in 5′-UTR regions of mRNAs6,7. More than 60% 
of the human transcriptome has been predicted to be under miR 
regulation, thus making this post-transcriptional control pathway as 
important as protein pathways in the regulation of cell functions2. 
It is clear that miRs have essential roles in regulating diverse functions 
in normal and diseased cells8,9.
L1 belongs to the most abundant class of autonomous transposable 
elements10. Human L1 contains two open reading frames, ORF1 and 
ORF2, which encode a protein with RNA-binding and nucleotide 
acid–chaperone activity (ORF1)11 and a protein with endonuclease 
and reverse-transcriptase activities (ORF2)12–15, respectively. 
L1 mobilizes replicatively from one location in the genome to another 
by a ‘copy-and-paste’ mechanism, and it has been proposed to be a 
remnant of an ancient retrovirus12,16. Active and inactive L1s have 
been implicated in the evolution of mammalian genomes and are 
linked to cell-based diseases, including cancer17–19. In addition, 
somatic L1 insertions are biased toward regions of cancer-specific 
DNA hypomethylation, thus suggesting that L1 insertions may 
provide a selective advantage during tumorigenesis20. Mechanisms 
that operate at different levels in gene-expression hierarchies have 
been selected to control transposition-mediated mutagenesis and 
mitigate the potential negative effects of newly inserted elements. 
In germ cells, a specific small-RNA subtype (piwi-interacting RNAs 
(piRNAs)) efficiently counteracts L1 activity, but these RNAs are not 
expressed in nongerm cells21,22. Somatic cells attenuate element mobi-
lization by DNA methylation of the L1 promoter23. Other methods 
of regulation are mediated by APOBEC proteins24,25, microproces-
sor interactions26 and Ago-mediated RNA interference in mouse 
embryonic stem cells27. L1-promoter silencing is greatly attenuated, 
and L1 transcription is reactivated in hypomethylated cells, such as 
cancer cells and tumor-initiating cells, and is also reactivated during 
reprogramming28–30. Because miRs act as regulators of gene expres-
sion and in antiviral defense mechanisms, we posited that they 
may also protect nongerm cells from encoded pathogenic assaults, 
such as L1 retrotransposition.
Here we show that miRs indeed bind directly to L1 ORF2 RNA, 
thus leading to decreases in full-length (FL) L1 RNA as well as 
de novo retrotransposition and integration events. Thus, we have 
uncovered a new mechanism in which miRs restrict L1 mobiliza-
tion and L1-associated mutations in cancer cells, cancer-initiating 
cells and iPSCs.
RESULTS
iPSCs	express	elevated	L1	ORF2	levels
iPSCs and human embryonic stem cells (hESCs) are characterized 
by a global genomic hypomethylation state as well as the specific 
hypomethylation of the L1 promoter28. In order to assess L1 activity 
1Department of Molecular Biology and Biochemistry, Francisco J. Ayala School of Biological Sciences, University of California, Irvine, Irvine, California, USA.  
2Regulus Therapeutics, San Diego, California, USA. 3These authors contributed equally to this work. Correspondence should be addressed to I.M.P. (imp@uci.edu).
Received 22 December 2014; accepted 19 August 2015; published online 14 September 2015; doi:10.1038/nsmb.3090
miR-128 represses L1 retrotransposition by binding 
directly to L1 RNA
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Long	interspersed	element	1	(LINE-1	or	L1)	retrotransposons	compose	17%	of	the	human	genome.	Active	L1	elements	are	
capable	of	replicative	transposition	(mobilization)	and	can	act	as	drivers	of	genetic	diversity.	However,	this	mobilization	is	
mutagenic	and	may	be	detrimental	to	the	host,	and	therefore	it	is	under	strict	control.	Somatic	cells	usually	silence	L1	activity		
by	DNA	methylation	of	the	L1	promoter.	In	hypomethylated	cells,	such	as	cancer	cells	and	induced	pluripotent	stem	cells	
(iPSCs),	a	window	of	opportunity	for	L1	reactivation	emerges,	and	with	it	comes	an	increased	risk	of	genomic	instability	and	
tumorigenesis.	Here	we	show	that	miR-128	represses	new	retrotransposition	events	in	human	cancer	cells	and	iPSCs	by	binding	
directly	to	L1	RNA.	Thus,	we	have	identified	and	characterized	a	new	function	of	microRNAs:	mediating	genomic	stability	by	
suppressing	the	mobility	of	endogenous	retrotransposons.
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in iPSC lines, we first developed an efficient RNA-only (miR and 
mRNA) reprogramming strategy, as a means to obtain iPSCs from 
skin fibroblasts (RNA-iPSCs) (Fig. 1a). In brief, RNA-iPSCs are repro-
grammed from human skin fibroblasts by a single transfection of an 
miR cocktail (miR-200c, miR-302a–d and miR-369)31 and subsequent 
daily transfections of mature mRNA transcripts encoding Klf4, Oct4, 
Sox2, c-Myc and Lin28 for 10–12 d, until the formation of mature 
iPSC colonies32 (Fig. 1b). The RNA-iPSCs express the cell-surface 
proteins TRA-1-60 and SSEA4 and the mRNAs of the transcription-
factor genes POU5F1 (here denoted OCT4), NANOG, LIN28A, SOX2, 
DNMT3B, FOXD3 and TERT, which are associated with pluripotency, 
at abundance levels similar to those found in hESCs (H9 cells) and 
commercially available iPSC lines (IMR-90) (Fig. 1b–d).
L1 activity in the generated iPSC lines (RNA-iPSCs) as well as 
IMR90, H9 and a teratoma cell line (Tera-1) was elevated, and all lines 
expressed L1 RNA at orders of magnitude higher than did parental 
skin (hBJ) cells (Fig. 1e). These results support the conclusion that 
reprogramming by different methodologies renders cells vulnerable 
to genomic instability caused by retrotransposition.
Identification	of	retrotransposition-repressor	miRs
We have shown previously that miRs can directly target hepatitis C 
viral RNA to repress viral replication33, thus raising the possibility 
that miRs could similarly repress L1 activity in hypomethylated 
somatic cells. Furthermore, depletion of three of the main proteins 
involved in miR biogenesis and miR function (Dicer, DGCR8 
and Ago) in different cell types results in significantly increased 
L1 activity26,27. To test whether miRs regulate L1 activity in somatic cells, 
we designed a lentiviral-based knockdown strategy in which libraries 
of expressed short hairpin RNAs (shRNAs) with anti-miR activity 
were used to neutralize endogenous miRs in HeLa cells. This approach 
favors a physiologically relevant response by avoiding potential arti-
facts resulting from ectopic overexpression occurring in miR-mimic 
library screens. We used a reporter construct encoding FL L1 mRNA 
and a luciferase retrotransposition-indicator cassette to identify miRs 
involved in repressing L1 activity34 (Supplementary Data Set 1). 
The luciferase protein can be translated into a functional enzyme only 
after retrotransposition of a spliced L1 transcript, thus allowing the 
quantification of cells with new retrotransposition events in culture34. 
We used a cotransfected Renilla reporter construct to normalize 
for potential differences in cell proliferation. Transient transfec-
tion of the reporter plasmids into the isolated shRNA anti-miR– 
transduced HeLa clones identified clones with significantly higher 
luciferase activity indicative of enhanced L1 retrotransposition activ-
ity (Fig. 2a). Twice in independent clones, we identified a capacity of 
anti–miR-128 to derepress L1 activity at a significant level (Fig. 2a). 
We verified that HeLa cells express miR-128 (Supplementary Fig. 1), 
and we validated the primary screen data by generating anti–miR-128 
shRNA lentiviruses at high titer, transducing them into HeLa cells 
and then selecting with puromycin. We observed a highly significant 
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Figure 1 L1 activity is derepressed in  
hESCs, iPSCs and teratoma cells.  
(a) Schematic diagram of the RNA-only  
reprogramming protocol in human  
fibroblasts. Human BJ foreskin fibroblasts  
(hBJ) are reprogrammed into RNA-iPSCs  
by initial transfection with a cocktail of  
miRs (miR-200c, miR-302s and miR-369  
family); this is followed by transfection of  
transcription-factor mRNAs (encoding Klf4,  
Oct4, Sox2, c-Myc and Lin28) for 10–12 d.  
(b) Phase-contrast images of RNA-iPSCs on  
days 3, 5, 8 and 10 of reprogramming.  
Immunofluorescence staining of RNA-iPSCs on day 10 for the surface pluripotency-associated markers TRA-1-60 and SSEA-4. Scale bars, 400 µm. 
(c) mRNA expression levels, determined by RT-PCR, of the pluripotency-associated genes OCT4, NANOG, LIN28A, SOX2, DNMT3B, FOXD3 and TERT 
relative to β-2-microglobulin (B2M) mRNAs in H9 hESCs, IMR90-1 iPSCs, RNA-iPSCs and hBJ fibroblasts. One representative experiment of three is 
shown. (d) Quantification of mRNA levels of NANOG, SOX2 and OCT4 in hBJ fibroblasts, H9 hESCs, IMR90-1 iPSCs and seven RNA-iPSC lines by qPCR, 
normalized to B2M. (n = 2 technical replicates; bars represent range of values). (e) Quantification of L1 ORF2 RNA in hBJ fibroblasts, Tera-1 teratoma 
cells, H9 hESCs, IMR90-1 iPSCs and three RNA-iPSC lines by qPCR, normalized to B2M (n = 2 technical replicates; bars represent range of values).
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increase in luciferase activity in cells express-
ing anti–miR-128 compared to cells express-
ing endogenous miR-128 (positive control) 
or cells that were not transduced with the 
reporter construct (negative control), thus 
indicating that the neutralization of miR-128 
strongly derepressed L1 activity (Fig. 2b). 
In addition, we characterized the effect 
of miR-128 neutralization by quantifying 
colony formation by essentially the same methodology with a tran-
scription-and-translation cassette based on the neomycin-resistance 
gene (G418)35 instead of the luciferase gene (Fig. 2c). The colony- 
formation assay also is a functional assay reflecting the in vivo 
levels of retrotransposition and integration into the genome; 
neomycin resistance is conferred only by active retrotransposition and 
an integration event. We observed an ~200% increase in the number 
of neomycin-resistant colonies in cells with anti–miR-128 compared 
to HeLa cells with endogenous miR-128 levels (control), thus indicat-
ing higher rates of L1 activity and active retrotransposition in cells in 
which miR-128 is neutralized (Fig. 2c). Last, we quantified the relative 
levels of L1 ORF2 RNA (in principle either genomic RNA or mRNA) 
by quantitative PCR (qPCR) analysis in cells stably transduced with 
anti–miR-128 compared to cells with endogenous miR-128 levels 
(positive control). To augment the low endogenous L1 levels, we 
transfected HeLa cells expressing anti–miR-128 or not with the 
L1 construct encoding FL L1 RNA, driven by the L1 native promoter 
(pWA355). We observed ~600% higher levels of L1 ORF2 RNA in cells 
expressing anti–miR-128 than in control cells that did not express 
anti–miR-128 (positive) or did not express the L1 transcript itself 
(negative), as normalized to β-2-microglobulin RNA levels (Fig. 2d). 
These combined data support the conclusion that neutralization of 
endogenously expressed miR-128 results in increased L1 retrotrans-
position and integration activity.
miR-128	is	a	specific	modulator	of	L1	activity
Although bioinformatics analyses failed to identify perfect seed 
matches in the 3′ UTR of L1 mRNA, they revealed a potential non-
canonical miR-128 seed sequence in the coding region (ORF2) of 
L1 mRNA (Fig. 3a). We determined the effects of miR-128 neutralization 
or overexpression on the levels of L1 transcript and retrotransposition 
activity by transducing HeLa cells with constructs expressing miR-128 
mimics, anti–miR-128 shRNAs or control sequences. Because HeLa 
cells express low endogenous L1 activity, we transiently transfected 
a construct (pJM101/L1RP) encoding FL wild-type (WT) L1 under 
control of the highly active CMV promoter and monitored the 
effects of miR-128 or anti–miR-128 on L1 RNA. Stably transduced 
cells expressing anti–miR-128 exhibited significantly higher levels 
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Figure 2 Identification of miRs that regulate 
L1 retrotransposition. (a) Primary screen 
determining L1 retrotransposition activity in 
HeLa cells transduced with a lentiviral-based, 
miR-neutralizing shRNA library, then selected 
and clonally expanded. Each well represents 
the neutralization of a single endogenously 
expressed miR. Dashed and dotted lines indicate 
luciferase activity for positive (L1 luciferase 
reporter plasmid in nontransduced HeLa 
cells) and negative controls (nontransduced 
HeLa cells not expressing the L1 luciferase 
reporter), respectively. Anti–miR-128 expression 
(indicated by boxes) correlated with significantly 
higher luciferase activity relative to controls and 
was cloned out from two independent wells with 
100% sequence identity. Data are shown as 
mean relative luciferase activity normalized to 
negative control. Error bars, s.e.m. *P < 0.05 by 
two-tailed Student’s t test (n = 3 independent 
cell cultures and experiments). (b–d) Secondary 
screen in HeLa cells lentivirally transduced 
with anti–miR-128 or control sequence and 
transfected with L1 reporter plasmids (pWA355 
in b and d; pJM101/L1RP in c). Error bars, 
s.e.m. *P < 0.05; ***P < 0.001 by two-tailed 
Student’s t test. (b) Relative luciferase activity 
normalized to that of negative control (n = 5 
independent cell cultures and experiments). 
(c) Level of active retrotransposition of L1, 
determined by change in colony count of 
neomycin-resistant foci (n = 3 independent 
experiments). (d) Relative expression levels 
of ORF2 RNA, determined by qPCR and 
normalized to B2M (n = 3 independent cell 
cultures and experiments).
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of L1 RNA than control sequence, because endogenously expressed 
miR-128 levels were neutralized, and L1 RNA therefore was dere-
pressed (Fig. 3b). Conversely, cells expressing miR-128, compared 
to controls, repressed L1 RNA expression (Fig. 3b). To exclude the 
possibility that miR-128 overexpression above physiological levels 
may have led to secondary effects of lentiviral miR-128 modulation 
that could confound the results, we transfected anti–miR-128 
oligonucleotides or synthetic miR-128 mimics into HeLa cells and 
determined L1 ORF2 RNA expression 48 h later. We observed sig-
nificant derepression of L1 ORF2 RNA in cells transfected with anti– 
miR-128 oligonucleotide (Supplementary Fig. 2a) and repression 
of L1 ORF2 RNA in cells transfected with the synthetic miR-128 
mimic (Supplementary Fig. 2a). In addition, we tested the effect of 
miR-128 on FL L1 RNA by analyzing expression levels of the 5′ UTR 
and ORF1 of L1, in addition to ORF2, in HeLa cells stably trans-
duced with miR-128, anti–miR-128 or control miRs. In cells in which 
miR-128 was overexpressed, levels of 5′-UTR, ORF1 and ORF2 RNA 
were significantly decreased (Fig. 3d), whereas cells in which miR-128 
had been neutralized showed substantially higher 5′-UTR, ORF1 and 
ORF2 expression levels (Fig. 3d). To establish that miR-128 indeed 
regulates the full-length transcript, we performed semiquantitative 
reverse-transcription PCR (RT-PCR), analyzing the expression levels 
of the FL 6-kb L1 RNA in HeLa cells, in which L1 was introduced. 
Anti–miR-128 enhanced FL L1 RNA (Fig. 3e), whereas miR-128, 
compared to a control miR, potently decreased FL L1 RNA expression 
levels (Fig. 3e). We verified that miR-modulated HeLa cells indeed 
overexpressed (miR-128) or expressed decreased levels of miR-128 
(anti–miR-128) by performing miR-128–specific qPCR and analyzing 
effects on an additional downstream miR-128 target (Bmi1 (ref. 36)) 
(Supplementary Fig. 3). In addition, we verified that the L1 plasmid 
was introduced into miR-expressing HeLa cells at equal levels, by 
quantifying levels of construct backbone (hygromycin) by qPCR and 
colony-formation assays (Supplementary Fig. 4). L1 ORF1 protein 
levels also were higher in cells transfected with anti–miR-128 and were 
lower in cells transfected with miR-128, consistently with RNA abun-
dance (Fig. 3b–f). Furthermore, cells transduced with anti–miR-128, 
compared to controls, exhibited a significantly higher number of 
neomycin-resistant colonies, and cells transduced with miR-128 had 
a significantly lower number of neomycin-resistant colonies, consist-
ently with lower rates of retrotransposition (Fig. 3g). These combined 
data support the conclusion that miR-128 induction or neutraliza-
tion results in a corresponding decrease or increase, respectively, in 
L1 RNA, protein and retrotransposition, and they establish a role 
of miR-128 as a specific modulator of L1 activity. Tera-1 cells are 
derived from a testicular teratoma and have high endogenous levels 
of L1 activity15 (Fig. 1e and Supplementary Fig. 1). We used Tera-1 
cells to provide a proof of principle regarding endogenous L1 regula-
tion: we predicted that if we could use miR-128 to achieve signifi-
cant reduction of L1 activity in a cell type with high L1 expression, 
then miR-128 would probably decrease L1 activity in other cancer 
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Figure 3 miR-128 represses L1 activity, whereas miR-128 neutralization derepresses L1 retrotransposition in various cell lines. (a) Schematic of 
potential miR-128–binding site in ORF2 of L1 RNA. (b) Relative RNA levels of L1 ORF2 RNA in HeLa cells stably transduced with miR constructs  
and L1-Neo reporter plasmid (pJM101/L1RP). Error bars, s.e.m. (n = 4 independent cell cultures and experiments). (c) Relative levels of FL L1 RNA  
(5′ UTR, ORF1 and ORF2) in stably transduced HeLa cells. Error bars, s.d. (n = 3 technical replicates). (d) Semiquantitative RT-PCR analysis of  
FL L1 RNA (6 kb) in stably transduced HeLa cells. Relative levels are quantified. One representative experiment of three is shown. (e) Immunoblot 
analysis of ORF1 and α-tubulin protein levels in stably transduced HeLa cells, 48 h after transfection. Relative levels are quantified. (f) Number of 
neomycin-resistant colonies as a measure of active L1 retrotransposition, shown as percentage change relative to control. Error bars, s.e.m. (n = 4 
independent cell cultures and experiments). (g) Relative ORF2 RNA levels in Tera-1 cells stably transduced with miR constructs. Error bars, s.e.m. (n = 3  
independent cell cultures and experiments for anti–miR-128; n = 5 independent cell cultures and experiments for miR-128). (h) Relative expression 
levels of the ORF2 RNA in CCICs transiently transfected with miR mimics. Error bars, s.d. (n = 4 technical replicates). Throughout figure, *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001 by two-tailed Student’s t test. Uncropped versions of blots are shown in Supplementary Data Set 2.
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cell lines as well. Stably transduced Tera-1 
cells expressing anti–miR-128 shRNAs, com-
pared to controls, significantly derepressed 
L1 ORF2 RNA expression, and miR-128 
significantly repressed L1 ORF2 RNA 
expression (Fig. 3h). Transient transfec-
tion of anti–miR-128 or miR-128 (Supplementary Fig. 2b) and 
quantification of FL L1 RNA (Supplementary Fig. 2c) confirmed 
these results. Furthermore, because tumor-initiating cells can drive 
tumor progression37, regulation of L1-induced mutagenesis of such 
cell types would be of importance. We found that transient trans-
fection of colon cancer–initiating cells (CCICs) with miR-128 
significantly reduced L1 RNA expression, whereas miR-128 neu-
tralization by anti–miR-128 enhanced L1 RNA expression relative 
to that of controls (Fig. 3h). In addition, we analyzed the effect of 
miR-128 on L1 activity in two additional tumor cell lines (non–small 
cell lung cancer cells (H23) and transformed human embryonic 
kidney cells (HEK293T)). As expected, miR-128 regulated L1 RNA 
expression in H23 and HEK293T cells in a similar manner as that 
observed for HeLa, Tera-1 and CCIC cells (Supplementary Fig. 2d). 
In summary, these results support the conclusion that miR-128 is a 
specific modulator of induced as well as endogenous L1 RNA levels in 
cancer cells, teratoma cells and CCICs, and that miR-128 additionally 
regulates L1 ORF1 protein levels and de novo L1 retrotransposition 
and integration.
miR-128	represses	L1	activity	in	iPSCs
Finally, we wished to test whether miR-128 could be used as a tool 
to decrease the high L1 activity, as determined by the high ORF2 
expression levels observed in iPSCs (Fig. 1e). miR-128 significantly 
decreased L1 ORF2 RNA expression in four different iPSC lines 
(reprogrammed with KOSM factors or RNA transfections) compared 
to parental control-miR iPSC lines (Fig. 4a). In contrast, anti–miR-128 
substantially enhanced L1 ORF2 RNA expression in all iPSC lines 
compared to parental control-miR iPSCs (Fig. 4a). We verified 
endogenously expressed miR-128, as well as expression levels of 
miR-128 in miR-128-iPSCs and anti–miR-128-iPSCs as previously 
described (Supplementary Figs. 3–5). We next tested the effect 
of miR-128 modulation on FL L1 RNA degradation in iPSCs, as 
determined by expression levels of the 5′ UTR, ORF1 and ORF2 by 
qPCR, and found that miR-128 significantly decreased the expres-
sion of FL L1 RNA (Fig. 4b), whereas anti–miR-128 substantially 
increased the expression of FL L1 RNA (Fig. 4b). In addition, miR-128 
decreased L1 ORF1 protein expression, and anti–miR-128 increased 
ORF1 protein expression in iPSCs, as determined by immunoblot 
analysis (Fig. 4c). Finally we wished to determine de novo ret-
rotransposition events in iPSCs. To this end, we generated stable 
miR-128, anti–miR-128 and control-miR iPSC lines, into which we 
introduced the neomycin-resistance L1 reporter cassette and meas-
ured new retrotransposition and integration events of L1 in iPSCs. 
miR-128 significantly decreased retrotransposition and integra-
tion of L1 into the genome of iPSCs (Fig. 4d), and neutralization 
of miR-128 strongly increased retrotransposition, as determined by 
colony-formation assays (Fig. 4d). These results suggest that miR-128 
is a specific regulator of endogenous L1 RNA levels, regulating 
L1 ORF1 protein levels and de novo retrotransposition and the 
integration of L1 into the genome of iPSCs.
miR-128	represses	L1	activity	by	direct	binding	to	L1	RNA
miR-128 could potentially regulate L1 expression by directly inter-
acting with L1 RNA, regulating expression of other proteins that 
regulate L1, or both. To address the possibility that miR-128 directly 
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Figure 4 miR-128 represses L1 activity, 
whereas miR-128 neutralization derepresses 
L1 retrotransposition in iPSCs. (a) Relative 
expression levels of ORF2 RNA in IMR90 and 
RNA-iPSCs 1, 3 and 7, transiently transfected 
with miR mimics or inhibitors. Error bars, 
s.d. (n = 3 technical replicates). (b) FL L1 
RNA expression levels determined in iPSCs 
transiently transfected with miR mimics or 
inhibitors by 5′-UTR, ORF1 and ORF2 qPCR 
analysis. Error bars, s.d. (numbers of technical 
replicates: n = 4 for RNA-iPSCs except miR- 
128 ORF2, for which n = 3; n = 3 for IMR90, 
except anti–miR-128 ORF1 and anti–miR-128 
ORF2, for which n = 4). (c) Immunoblot analysis 
of ORF1 and α-tubulin protein levels in iPSCs 
transduced with miR constructs, 48 h after  
L1-Neo reporter transfection. Relative levels are 
quantified. One representative example of two is 
shown. (d) Number of neomycin-resistant iPSC 
colonies transduced with miR constructs and 
transfected with the L1-Neo reporter plasmid, 
as a measure of active L1 retrotransposition, 
shown as percentage change relative to control.  
Error bars, s.e.m. (n = 3 independent 
experiments). Throughout figure, *P < 0.05; 
***P < 0.001; ****P < 0.0001 by two-tailed 
Student’s t test. Uncropped versions of blots  
are shown in Supplementary Data Set 2.
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interacts with L1 RNA, we introduced a silent mutation into the 
putative miR-128–binding site in ORF2 of L1 RNA (Supplementary 
Fig. 6a). Luciferase activity was significantly lower than that of con-
trols in HeLa cells transfected with the WT L1 construct and mature 
miR-128, thus supporting the conclusion that miR-128 can bind to 
the WT L1 RNA sequence and prevent retrotransposition (Fig. 5a). 
In contrast, HeLa cells transfected with the mutant L1 RNA-binding 
site and either mature miR-128 or control-miR mimics exhibited 
luciferase activity at the same levels as in the WT L1 and 
control-miR cells, consistently with miR-128 no longer binding and 
repressing reporter-gene expression. As expected, L1 RNA with a 
perfect match at the miR-128–binding site was strongly repressed by 
miR-128 (Fig. 5a). To extend the analysis, we mutated the miR-128– 
binding site in the L1 construct used in Figure 3 to increase the 
levels of L1 RNA in HeLa cells. The WT L1 expression construct 
and that with a mutated miR-128–binding site were transfected into 
HeLa cells stably transduced with miR-128, anti–miR-128 shRNA 
or control miR. Consistently with previous results, anti–miR-128 
derepressed L1 ORF2 RNA expression levels, and miR-128 
repressed L1 ORF2 RNA expression levels when the WT L1 plasmid 
was transfected into HeLa cells (Fig. 5b). In contrast, the construct 
with the mutated miR-128–binding site showed that expression of 
miR-128 or control miR failed to downregulate L1 ORF2 levels, 
thus supporting the conclusion that the introduced mutation at 
the miR-128–binding site abrogated interaction between miR-128 and 
the target site, thus resulting in higher levels of L1 RNA (Fig. 5b). 
The effect of the mutation of the miR–binding site on L1 retro-
transposition activity also supported this conclusion: HeLa cells 
overexpressing miR-128 and the WT plasmid exhibited fewer 
neomycin-resistant colonies and lower retrotransposition relative to 
controls, as expected (Fig. 5c). However, when the mutated plasmid 
was transfected into HeLa cells overexpressing miR-128, or control 
miR, significantly higher numbers of neomycin-resistant colonies 
formed (Fig. 5c). Introduction of anti–miR-128, compared to con-
trols, neutralized endogenously expressed miR-128 and enhanced 
L1 expression, as previously shown (Fig. 3b). In a similar manner, 
induced miR-128 and endogenously expressed miR-128 were inca-
pable of binding and repressing mutant L1, thus resulting in two-
fold-higher L1 expression levels than in controls. We verified the 
transfection and transduction efficiency of miR-modulated HeLa 
cells, as described previously (Supplementary Figs. 3 and 4). Because 
miR-128 is unable to bind to mutated L1 ORF2 RNA and repress 
RNA active retrotransposition, these data support the conclusion 
that miR-128 represses L1 RNA retrotransposition and integra-
tion via a direct interaction with the target site on the ORF2 RNA. 
L1 RNA in miR-128 mutant-site cells is higher than in controls 
because miR-128 (overexpressed or endogenously expressed) can-
not bind and repress mutant L1 RNA.
miR-128	interacts	with	L1	RNA
To directly test whether miR-128 binds to L1 RNA, we isolated Ago 
complexes containing miRs and target mRNAs by immunopurifica-
tion from cells expressing miR-128 or anti–miR-128 and assessed 
relevant complex occupancy by L1 RNA. As expected, the relative 
level of total L1 RNA was lower in Tera-1 cells stably overexpressing 
miR-128 than in those expressing anti–miR-128 (Fig. 6a). Despite the 
lower levels of L1 RNA, Ago-bound L1 RNA was significantly higher 
in cells overexpressing miR-128 than in cells in which miR-128 was 
downregulated by anti–miR-128 (Fig. 6b). When we corrected for the 
higher levels of L1 ORF2 in Tera-1 cells treated with anti–miR-128, 
the difference in bound L1 RNA was even more significant (corrected 
anti–miR-128). These results provide direct evidence that miR-128 
binds to L1 RNA. We repeated the Ago immunopurification experi-
ments in HeLa cells stably transduced with anti–miR-128 or miR-128, 
which were transfected with L1 expression plasmids (encoding either 
WT L1 or L1 with a mutant miR-128–binding site). Overexpression 
of miR-128, compared to transduction with anti–miR-128, led to 
significantly lower levels of total WT L1 RNA, as observed previously 
(Fig. 6c). Also as expected, the relative level of total mutant L1 RNA 
was higher than that of WT L1 RNA in cells transduced with 
miR-128. The relative level of total L1 RNA was lower in HeLa cells 
stably overexpressing miR-128 than in those expressing anti–miR-128 
(Fig. 6c,d). When we corrected for the higher levels of L1 ORF2 in 
HeLa cells treated with anti–miR-128, the difference was even more 
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Figure 5 miR-128 represses L1 activity by binding directly to ORF2 RNA. 
(a) Relative luciferase levels in HeLa cells transfected with constructs 
expressing Gaussia luciferase fused to the predicted WT binding site of 
miR-128; a mutated binding site in the L1 open reading frame; positive-
control sequence corresponding to the 22-nt perfect match of miR-128; 
and control or miR-128 constructs, in the combinations indicated,  
48 h after transfection. Error bars, s.e.m. (n = 3 independent cell cultures 
and experiments). (b) Relative expression levels of ORF2 RNA in HeLa 
cells transduced with lentiviral constructs encoding a control miR or 
miR-128 and transfected with L1-Neo reporter WT plasmid or mutant 
L1-Neo reporter plasmid containing the mutated miR-128–binding 
site (n = 2 independent cell cultures and experiments; bars represent 
range of values). (c) Change in colony count in L1-transfected HeLa 
cells transduced with control-miR or miR-128 mimic constructs 
and transfected with the L1-Neo reporter plasmid encoding WT or 
mutated miR28–binding sites, as a measure of the level of active L1 
retrotransposition. Results are shown as percentage change and are 
normalized to control miR–transfected cells. Error bars, s.e.m. (n = 3 
independent cell cultures and experiments). Throughout figure,  
*P < 0.05; **P < 0.01; ****P < 0.0001 by two-tailed Student’s t test.
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significant (Fig. 6d; corrected anti–miR-128). 
In addition, even though mutant L1 RNA was 
expressed at higher levels in cells transduced 
with miR-128 compared to WT L1, it immu-
nopurified less efficiently than WT L1 RNA from miR-128–transduced 
cells (Fig. 6c,e). When we corrected for the higher levels of L1 ORF2 
in mutant-treated HeLa cells, the difference was even more significant 
(Fig. 6e; corrected anti–miR-128). These results demonstrate that 
the putative miR-128–binding site in the ORF2 region of L1 RNA is 
indeed the functional binding site. A control, constitutively expressed 
transcript of the GAPDH gene did not show altered levels of total 
RNA in cells transduced with miR-128 or anti–miR-128, or relative 
differences in Ago immunopurification (Supplementary Fig. 2e).
DISCUSSION
Our findings complement previous work on L1 post-transcriptional 
regulation by Caceres and colleagues26,38, which identified multi-
ple direct binding sites in the L1 5′ UTR for the microprocessor- 
complex subunit DGCR8 (ref. 38), which binds and cleaves 
L1 RNA26. Our results expand this work and suggest a scenario in 
which DGCR8 binds to double-stranded RNA structures of the 
5′ UTR of L1 RNA and cleaves L1 in the nucleus; L1 transcripts that 
escape DGCR8-mediated control are transported out of the nucleus, 
where a second miR-mediated mechanism regulates their expres-
sion levels and represses their effects in the cytoplasm. It is pos-
sible that miR-128 also affects translational repression of L1 RNA 
and/or represses transcription of L1; however, our results indicate 
that RNA degradation is the main mechanism by which miR-128 
represses L1 activity.
Genomic alignment analysis of human, chimpanzee, rat and 
mouse sequences interestingly shows that the miR-128–binding site 
in L1 ORF2 is 100% conserved between humans and chimpanzees, 
and partly conserved (one or two mismatches) in mice and rats 
(Supplementary Fig. 6b). From our findings, we propose that miRs 
(miR-128) have adopted part of piRNAs’ role in nongerm cells21 by 
binding directly to the ORF2 of L1 RNA, thus resulting in L1 repression 
and decreasing the risk of genomic instability. These results suggest 
that miRs, in addition to being key regulatory molecules, have evolved 
to protect somatic cells (including cancer cells, cancer-initiating 
cells and iPSCs) from pathogenic RNA molecules originating from 
extracellular sources, such as RNA viruses, or from intracellular 
encoded sources, such as retrotransposons, thereby taking on an 
important function as protectors of genomic stability (Fig. 6f).
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online 
version of the paper.
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Figure 6 miR-128 binds directly to L1 ORF2 
RNA in cells. (a) Relative L1 ORF2 RNA levels 
in Tera-1 cells transduced with miR constructs, 
normalized to GAPDH. Error bars, s.e.m.  
(n = 3 independent cell cultures and 
experiments). (b) Relative fraction of L1 ORF2 
transcripts associated with Ago complexes, from 
the same lysates as in a, normalized to input 
levels. L1 ORF2 immunopurified (IP) fractions 
normalized to the levels of L1 ORF2 in input are 
shown as ‘corrected’. Error bars, s.e.m. (n = 3 
independent cell cultures and experiments).  
(c) Relative L1 RNA levels in HeLa cells 
transduced with miR constructs and L1 WT 
or mutant reporter plasmid, normalized to 
GAPDH. Error bars, s.e.m. (n = 3 independent 
cell cultures and experiments). (d,e) Relative 
fraction of L1 ORF2 transcripts associated 
with Ago complexes, from same lysates as 
in c, normalized to let-7 levels. L1 ORF2 
immunopurified fractions normalized to the 
levels of L1 ORF2 in input are shown as 
corrected. In d, error bars represent s.e.m. (n = 3 
independent cell cultures and experiments); in 
e, bars represent range (n = 2 independent cell 
cultures and experiments). Throughout figure, 
**P < 0.01; ***P < 0.001; ****P < 0.0001 
by two-tailed Student’s t test. (f) Model of the 
multifaceted role of miRs in defense against 
assault to cellular RNA by agents from the 
extracellular environment (virus) or intracellular 
encoded parasites such as L1 retrotransposons.
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ONLINE	METHODS
Induced pluripotent stem-cell reprogramming. iPSCs were generated from 
human foreskin fibroblasts (early-passage hBJ, discontinued, Stemgent) with an 
mRNA Reprogramming Kit (00-0071, Stemgent) in combination with a micro-
RNA Booster Kit (00-0073, Stemgent). The resultant iPSCs are termed RNA-iPSCs. 
hBJ cells were plated at a density of 5 × 104 cells per well of a six-well Matrigel-
coated plate (354277, Corning) and incubated at 37 °C and 5% CO2 for 24 h. The 
oxygen tension was then decreased from ambient to 5%, before the start of the 
transfection schedule. Throughout the protocol, medium was changed daily with 
Pluriton (00-0070, Stemgent) preconditioned with inactivated newborn human 
foreskin fibroblasts (GSC-3006G, GlobalStem) containing 300 ng/mL B18R 
(34-8185, eBiosciences) and 1× Pluriton supplement (stock 2,500×). All RNA 
transfections were carried out with a Stemfect Transfection Kit (00-0069, 
Stemgent). On day 0 of reprogramming, 70 pmol of miR cocktail was trans-
fected into the hBJ cells. 1 µg of mRNA cocktail (Oct4, Sox2, Klf4, c-Myc, Lin28, 
and nGFP at 3:1:1:1:1:1 stoichiometry) was transfected on days 1–3. On day 4, 
miR and mRNA cocktails were cotransfected. Daily mRNA-cocktail transfections 
continued from days 5–11. The time of appearance of the first colonies averaged 
from 10 to 14 d. RNA-iPSCs were maintained in Nutristem (01-0005, Stemgent).
Statistical analysis. Student’s t tests were used to calculate two-tailed P values. 
No multiple test correction was performed. Summary for P values: *P < 0.05; 
**P < 0.01; ***P < 0.001; ****P < 0.0001. Data are displayed as mean ± s.e.m. 
of biological replicates (n) as indicated. When number of experiments was <3, 
range of values is shown.
Cell culture. Human foreskin fibroblasts (hBJ, discontinued, Stemgent) were cul-
tured in DMEM with 10% FBS. IMR-90-1 (iPS(IMR90)-1, WiCell) and RNA-iPSCs 
were cultured in Nutristem (01-0005, Stemgent) on ES-qualified matrigel (354277, 
Corning). Tera-1 cells (HTB-105, ATCC) were cultured in McCoy’s 5A (16600-
082, Life Technologies) supplemented with 20% Cosmic Serum (SH3008702, 
Fisher Sci) and 1% Normocin (ant-nr-1, Invivogen). HeLa cells (CCL-2, ATCC) 
were cultured in EMEM (SH3024401, Hyclone) supplemented with 10% HI-FBS 
(FB-02, Omega Scientific), 5% Glutamax (35050-061, Life Technologies), 3% 
HEPES (15630-080, Life Technologies), and 1% Normocin (ant-nr-1, Invivogen). 
HEK293T cells (CRL-3216, ATCC) were cultured in DMEM supplemented 
with 10% HI-FBS (FB-02, Omega Scientific), 5% GlutaMAX (35050-061, Life 
Technologies) and 1% Normocin (ant-nr-1, Invivogen). Colon cancer-initiating 
cells (CCICs, a gift from M. Waterman) were verified and cultured as described 
in Sikandar et al.37. Briefly, CCICs were cultured as spheres in ultra–low attach-
ment flasks in DMEM/F12, N2 supplement (17502-048, Life Technologies), B27 
supplement (17504-044, Life Technologies), heparin (4 µg/mL, Sigma), epidermal 
growth factor (20 ng/mL), and basic fibroblast growth factor (20 ng/mL). H23 
cells (CRL-5800, ATCC) were cultured in RPMI-1640 (11875, Life Technologies), 
10% HI-FBS, 5% Glutamax, and 1% Normocin. All cells were cultured at 37 °C 
and 5% CO2 and routinely checked for mycoplasma. Cell lines were not independ-
ently authenticated in our laboratory.
Derepression L1 anti-miR library screen. HeLa cells were transduced with miR-
Zip Virus Library (MZIPPLVA, System Biosciences), selected with puromycin and 
split to single-cell dilutions. Luciferase reporter plasmids pWA355 (50 µg) as well 
as the normalization plasmid pGL4.74 (Renilla luciferase) were transfected with 
FuGENE HD (E2311, Promega), and results were read on a GloMax-multi reader 
(Promega) with the Dual-Glo Luciferase assay system (E2940, Promega).
RNA extraction and quantification of mRNAs. RNA was extracted with TRIzol, 
Zymogen Directzol, Qiagen RNeasy Kit or Qiagen miRNeasy Kit, according to 
the manufacturers’ instructions. mRNA levels were analyzed by qPCR with 
TaqMan One Step RT-PCR kit or SYBR Green (Life Technologies), relative to 
β-2-microglobulin (B2M), GAPDH or GUSB housekeeping genes and processed 
with the ∆∆Ct method. miR-128 levels were determined by miScript II RT 
and primer qPCR assay (Qiagen); miR-128 levels were normalized to RNU5A 
with the ∆∆Ct method.
RT-PCR. RNA was reverse transcribed into cDNA with a High-Capacity Reverse 
Transcriptase Kit with poly-dT primers (4368813, Life Technologies). cDNA was 
amplified with Q5 polymerase (M0494S, NEB) and specific primers for mRNA 
targets (OCT4, NANOG, LIN28A, SOX2, DNMT3B, FOXD3, TERT and FL L1 
relative to B2M) for 40 cycles according to the manufacturer’s protocol. PCR 
products were run on an 0.8% agarose gel and visualized with ethidium bromide. 
All uncropped RT-PCR gels can be found in Supplementary Data Set 2.
Plasmids and primers. Lists and details of plasmids and primers can be found 
in Supplementary Data Set 1.
Immunofluorescence staining. StainAlive TRA-1-60–specific antibody 
conjugated to DyLight 488 (09-0068, Stemgent) and StainAlive SSEA-4–specific 
antibody conjugated to DyLight 550 (09-0097, Stemgent) were used to iden-
tify and verify RNA-iPSCs. Validation of these antibodies is available on the 
manufacturer’s website.
Immunoblotting. Rabbit anti-human L1 ORF1p, custom generated by Genscript 
and validated by ELISA, was used at 1:1,000. Anti–α-tubulin (ab4074, Abcam), 
used as a loading control, was diluted 1:5,000; validation can be found on 
the manufacturer’s website. All uncropped immunoblots can be found in 
Supplementary Data Set 2.
Transfection and transduction of miRs. OptiMEM (31985070, Life 
Technologies) and TransIT-X2 transfection reagent (MIR-6004, Mirus Bio) or 
Lipofectamine RNAiMAX (13778075, Life Technologies) were used to com-
plex and transfect 20 µM miR-128 mimic or anti–miR-128 (C-301072-01 and 
IH-301072-02, Dharmacon) into HeLa (pJM101/L1RP cotransfected), Tera-1, 
HEK293T, H23 and iPSCs. VSVG-pseudotyped lentiviral vectors were made 
by transfection of 0.67 µg of pMD2-G (12259, Addgene), 1.297 µg of pCMV-
DR8.74 (8455, Addgene), and 2 µg of mZIP-miR-128 or mZIP-anti–miR-128 
(transfer plasmid) into HEK293T cells with Lipofectamine LTX with plus rea-
gent (15338030, Life Technologies). Viral supernatant was concentrated with 
PEG-it virus-precipitation solution (LV810A-1, System Biosciences) accord-
ing to the manufacturer’s instructions. Cells were transduced with viruses at 
high titer with polybrene (sc-134220, Santa Cruz Biotech) and spinoculation 
(800g at 32 °C for 30 min). Transduced cells were then selected and maintained 
with 3 µg/mL puromycin.
Colony-formation assay. Stable HeLa lines expressing miR-128, anti–miR-128 or 
scrambled control were transfected with pJM101/L1RP (containing a neomycin-
resistance retrotransposition-indicator cassette) per well with X-treme gene HP 
DNA transfection reagent (06366236001, Roche) according to the manufacturer’s 
instructions. Cells were selected with 500 µg/mL G418 (ant-gn-1, Invivogen). 
Neomycin-resistant colonies were fixed with cold 1:1 methanol/acetone and then 
visualized with May-Grunwald (ES-3410, Fisher) and Jenner-Giemsa staining 
kits (ES-8150, Fisher) according to the manufacturer’s protocol. Stable iPSC 
lines expressing miR-128, anti–miR-128 or scrambled control were transfected 
with pJM101/L1RP with Xtreme gene HP DNA transfection reagent according 
to the manufacturer’s instructions. Selection began with 25 µg/mL G418 72 h 
after transfection and was maintained with daily medium changes until nega-
tive-control (nontransfected) cells had died. Neomycin-resistant colonies were 
prepared as described above.
Mutation of the miR-128–binding site. For the mutation of the potential miR-
128–binding site in ORF-2 of the L1 reporter, the complete L1 reporter cas-
sette was excised from the pJM101/L1RP plasmid by SalI digest. The fragment 
was purified by gel extraction and inserted into the SalI-digested backbone of 
pcDNA3.1. The resultant plasmid pL1-Neo-Reporter was drastically reduced 
in size, thus allowing for the construction of a mutated fragment by fusion PCR 
and insertion into the pL1-Neo-Reporter. For the fusion PCR, the primers 
(sequences in Supplementary Data Set 1) were used to amplify the fragments 
with the Phusion PCR polymerase system (NEB). For the fusion, 2 µl of the 
first PCR was used as a template for the generation of the long fragment, with 
PCRI primer sense and PCRII primer antisense, and amplified by standard PCR 
with the Phusion PCR polymerase system (NEB). The fusion fragment includes 
the mutated miR-128, and it was purified by gel electrophoresis. The original 
ORF-2 sequence was replaced in the pL1-Neo-Reporter by the fusion fragment, 
by cutting the plasmid and the fusion fragment with restriction enzymes AfeI 
and EcoRI, and was then ligated.
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Luciferase assays (for direct miR binding analysis). WT L1, mutated L1, or 
positive-control sequences (Supplementary Fig. 6) were cloned into a dual- 
luciferase reporter plasmid (pEZX-MT05, Genecopoeia). 3 × 105 HeLa cells were 
forward-transfected with 0.8 µg of reporter plasmid (WT, mutated, Pos) and 
20 nM miR-128 mimic (Dharmacon) or control mimic (Dharmacon) with 
Attractene transfection reagent (301005, Qiagen) according to the manufac-
turer’s instructions. Relative Gaussia Luciferase and SEAP were determined 
with a Secrete-Pair Dual Luminescence Assay Kit (SPDA-D010, Genecopoeia). 
Luminescence was detected with a Tecan Infinite F200 Pro microplate reader.
Argonaute RNA immunopurifications (Ago RIPs). Immunopurification of Ago 
from HeLa and Tera cell extracts was performed with the 4F9 antibody (sc-53521, 
Santa Cruz Biotechnology), as described previously39,40. Briefly, 10-mm plates of 
80% confluent cultured cells were washed with buffer A (20 mM Tris-HCl, pH 8.0, 
140 mM KCl and 5 mM EDTA) and lysed in 200 µl of 2× buffer B (40 mM Tris-HCl 
pH 8.0, 280 mM KCl, 10 mM EDTA, 1% NP-40, 0.2% deoxycholate, 2× Halt 
protease-inhibitor cocktail (Pierce), 200 U/ml RNaseOUT (Life Technologies) 
and 1 mM DTT). Protein concentration was adjusted across samples with buffer 
B (20 mM Tris-HCl, pH 8.0, 140 mM KCl, 5 mM EDTA, pH 8.0, 0.5% NP-40, 
0.1% deoxycholate, 100 U/ml RNaseOUT (Life Technologies), 1 mM DTT and 
1× Halt protease-inhibitor cocktail (Pierce)). Lysates were centrifuged at 16,000g 
for 15 min at 4 °C, and supernatants were incubated with 10–20 µg of 4F9 anti-
body conjugated to epoxy magnetic beads (M-270 Dynabeads, Life Technologies) 
for 2 h at 4 °C with gentle rotation (nutator). After magnetic separation, the beads 
were washed three times for 5 min with 2 ml of buffer C (20 mM Tris-HCl, pH 8.0, 
140 mM KCl, 5 mM EDTA, pH 8.0, 40 U/ml RNaseOUT (Life Technologies), 
1 mM DTT and 1× Halt protease-inhibitor cocktail (Pierce)). After immunopu-
rification, RNA was extracted with miRNeasy kits (Qiagen), according to the 
manufacturer’s recommendations, and qPCR was performed with commercially 
available TaqMan assays for GAPDH and the let-7 miRNA as well as custom 
probes and primers for the L1 mRNA transcript. Results were normalized to their 
inputs or to let-7 miRNA, as a proxy for Ago immunopurification efficiency.
39. Hunter, S.E. et al. Functional genomic analysis of the let-7 regulatory network in 
Caenorhabditis elegans. PLoS Genet. 9, e1003353 (2013).
40. Hogan, D.J. et al. Anti-miRs competitively inhibit microRNAs in Argonaute 
complexes. PLoS ONE 9, e100951 (2014).
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